NEW YORK, Aug. 15, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company will present clinical data on its lead asset, Plinabulin, during a poster presentation at the International Association for the Study of Lung Cancer (IASLC) 19thWorld Conference on Lung Cancer, being held September 23 to 26, 2018, in Toronto. Abstract #13016 Title: `Plinabulin, a Novel Immuno-Oncology Agent Mitigates Docetaxel Chemotherapy-Induced-Neutropenia and...
|